ES2104909T3 - Nuevos derivados de heparina y proceso para la preparacion de los mismos. - Google Patents

Nuevos derivados de heparina y proceso para la preparacion de los mismos.

Info

Publication number
ES2104909T3
ES2104909T3 ES92908867T ES92908867T ES2104909T3 ES 2104909 T3 ES2104909 T3 ES 2104909T3 ES 92908867 T ES92908867 T ES 92908867T ES 92908867 T ES92908867 T ES 92908867T ES 2104909 T3 ES2104909 T3 ES 2104909T3
Authority
ES
Spain
Prior art keywords
heparin
show
equal
standard
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92908867T
Other languages
English (en)
Inventor
Christer Mattsson
Carl-Magnus Svahn
Michael Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Application granted granted Critical
Publication of ES2104909T3 publication Critical patent/ES2104909T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS DERIVADOS DE LA HEPARINA A PARTIR DE LA HEPARINA BOBINA O PORCINA QUE TIENEN UN PESO MOLECULAR IGUAL O MAYOR QUE LA HEPARINA ESTANDAR, LOS DERIVADOS PRESENTAN UN CONTENIDO DE AZUFRE QUE ES IGUAL O MAYOR QUE EL DE LA HEPARINA DE INICIACION O DE AL MENOS EL 13%, TIENEN UNA ACTIVIDAD ANTICOAGULANTE EN EL ENSAYO ANTI-FXA INFERIOR AL 10% DE LA HEPARINA ESTANDAR, MUESTRAN UNA RELACION DE ACTIVIDAD APTT SOBRE LA ACTIVIDAD ANTI FXA DE ENTRE 3 Y 35, MUESTRAN UNA PROLONGACION REDUCIDA DEL TIEMPO DE SANGRADO EN COMPARACION CON LA HEPARINA ESTANDAR (ELLO SE COMPROBO EN EL RABO DE UNA RATA DESPUES DE SU ADMINISTRACION) Y MUESTRAN MEJORAS EN LA PROPORCION DE DESARROLLO DE EFECTOS COLATERALES CORONARIOS EN PERROS IGUAL O MEJOR QUE LA HEPARINA USADA CLINICAMENTE. LA INVENCION TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION DE NUEVOS DERIVADOS DE HEPARINA BOBINA Y PORCINA. SE PRESENTA EL USO DE ESTE PRODUCTO PARA LA MANUFACTURACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES CORONARIAS ISQUEMICAS Y ENFERMEDADES VASCULARES RELACIONADAS Y PARA LA MEJORA DE LA PROPORCION DE DESARROLLO DE EFECTOS COLATERALES CORONARIOS.
ES92908867T 1991-04-18 1992-04-14 Nuevos derivados de heparina y proceso para la preparacion de los mismos. Expired - Lifetime ES2104909T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101155A SE9101155D0 (sv) 1991-04-18 1991-04-18 Novel heparin derivatives

Publications (1)

Publication Number Publication Date
ES2104909T3 true ES2104909T3 (es) 1997-10-16

Family

ID=20382487

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92908867T Expired - Lifetime ES2104909T3 (es) 1991-04-18 1992-04-14 Nuevos derivados de heparina y proceso para la preparacion de los mismos.

Country Status (12)

Country Link
US (2) US6150342A (es)
EP (1) EP0536363B1 (es)
JP (1) JP3278676B2 (es)
AT (1) ATE154614T1 (es)
AU (1) AU642626B2 (es)
CA (1) CA2084301C (es)
DE (1) DE69220442T2 (es)
DK (1) DK0536363T3 (es)
ES (1) ES2104909T3 (es)
GR (1) GR3024757T3 (es)
SE (1) SE9101155D0 (es)
WO (1) WO1992018545A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) * 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
AU2435795A (en) * 1994-05-06 1995-11-29 Glycomed Incorporated O-desulfated heparin derivatives, methods of making and uses thereof
DE69621528T2 (de) * 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
DE69931038T2 (de) * 1998-02-26 2006-11-23 Seikagaku Corp. Neue polysaccharidderivate, verfahren zu ihrer herstellung und medizinische zusammensetzungen die diese als aktives bestandteil enthalten
CZ20014665A3 (cs) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Prostředek s obsahem heparinu se střední molekulovou hmotností
US7608246B2 (en) * 2005-09-02 2009-10-27 The Brigham And Women's Hospital, Inc. Apolipoprotein E as an adjuvant for lipid antigens
US8592393B2 (en) 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US9387256B2 (en) 2010-04-16 2016-07-12 Momenta Pharmaceuticals, Inc. Tissue targeting
WO2011159770A2 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
US10016449B2 (en) 2013-05-28 2018-07-10 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
GB2515315A (en) * 2013-06-19 2014-12-24 Dilafor Ab New Processes
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
WO2025106117A1 (en) * 2023-11-17 2025-05-22 Glycos Biomedical Ltd. Medium molecular weight heparin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4948881A (en) * 1982-12-28 1990-08-14 Sanofi Process for the depolymerization and sulfation of polysaccharides
FR2538404B1 (es) * 1982-12-28 1985-08-23 Anic Spa
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
DE3744119A1 (de) * 1987-12-24 1989-07-06 Basf Ag Verwendung von polysulfatierten heparinen
IT1237518B (it) * 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate

Also Published As

Publication number Publication date
GR3024757T3 (en) 1997-12-31
AU642626B2 (en) 1993-10-21
US6150342A (en) 2000-11-21
JP3278676B2 (ja) 2002-04-30
DE69220442D1 (de) 1997-07-24
AU1646392A (en) 1992-11-17
US6326476B1 (en) 2001-12-04
WO1992018545A1 (en) 1992-10-29
DK0536363T3 (da) 1998-01-26
CA2084301C (en) 2005-10-25
EP0536363B1 (en) 1997-06-18
CA2084301A1 (en) 1992-10-19
SE9101155D0 (sv) 1991-04-18
JPH05508184A (ja) 1993-11-18
ATE154614T1 (de) 1997-07-15
DE69220442T2 (de) 1998-01-29
EP0536363A1 (en) 1993-04-14

Similar Documents

Publication Publication Date Title
ES2104909T3 (es) Nuevos derivados de heparina y proceso para la preparacion de los mismos.
ATE131176T1 (de) Sulfatierte polysaccharide, antikoagulierungs- und antikomplementärmittel, hergestellt aus fukanen aus braunen algen, und verfahren zu deren herstellung.
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
ATE161273T1 (de) Polysaccharidderivate von heparin, heparansulfate, ihre fraktionen und fragmente, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, welche diese enthalten
DE3486341D1 (de) Derivate von Dextran mit antikoagulierenden und antikomplementären Eigenschaften, ihre Herstellung und ihre biologischen Anwendungen.
ATE210154T1 (de) Derivate von k5 polysaccharid mit hoher, blutgerinnungshemmender wirkung
ATE224918T1 (de) Zusammensetzung zur hemmung der thromboseentstehung
IT1230582B (it) Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
RU2216548C2 (ru) Смесь линейных олигосахаридов, полученная из дерматансульфата, фармацевтическая композиция, обладающая антитромботическим действием, и способ лечения
DE69025691D1 (de) Einschlusskomplexe mit Silybinin, ihre Herstellung und pharmazeutische Präparate, die diese enthalten
Wright An evaluation of anticoagulant therapy
JPS6322801A (ja) Ｅｄｔａ不含のヘパリン、ヘパリン分画ならびに断片、それらの製造法及びそれらを含有する医薬品組成物
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
IT1209945B (it) Derivati piridinici e procedimenti per la loro preparazione
KR910001040A (ko) 항응고요법을 위한 활성물질인 암블리옴민
US2976212A (en) Hyaluronidase with heparin or heparinoids in ointment compositions
DE4430204A1 (de) Arzneimittel, welches als Gegenmittel für Blut-Antikoagulanzien geeignet ist und seine Verwendung
FR2380275A1 (fr) Nouveaux composes imidazoles et leurs derives sulfoxydes et sulfones correspondants, leur preparation et compositions pharmaceutiques les contenant
ATE112276T1 (de) Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ES487818A0 (es) Procedimiento para la preparacion de nuevas sustancias analogas de prostaciclina
McGraw et al. Twofold effect of corticotropin (ACTH) on blood clotting and its implications in surgery
Allalouf et al. Anticoagulant properties of an acid mucopolysaccharide preparation isolated from rat kidney
Borowska et al. Impairment of primary haemostasis by low molecular weight heparins in rats
SE9003181D0 (sv) Use of heparin fraction
Md et al. Bilateral coronary thrombosis in the absence of inducible coronary spasm, thrombocytosis, coagulation abnormalities, or angiographic evidence of coronary artery disease: previously undescribed method of myocardial infarction

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 536363

Country of ref document: ES